Astrazeneca (AZN) Cash from Restructuring (2009 - 2014)

Astrazeneca has reported Cash from Restructuring for 6 years, with the latest figure at $85.8 million in Q2 2014.

• On a quarterly basis, Cash from Restructuring rose 1325.57% year-over-year to $85.8 million in Q2 2014; TTM through Sep 2016 was $85.8 million, a N/A change from a year earlier, with the FY2016 full-year figure at -$13.0 million, changed N/A from the prior year.
• Cash from Restructuring was $85.8 million for Q2 2014 at Astrazeneca, up from -$102.0 million in the prior quarter.
• The five-year high for Cash from Restructuring was $85.8 million in Q2 2014, with the low at -$102.0 million in Q1 2014.
• Average Cash from Restructuring over 5 years is -$3.7 million, with a median of -$3.0 million recorded in 2013.
• The largest YoY upside for Cash from Restructuring was 1325.57% in 2014 against a maximum downside of 3300.0% in 2014.
• Over 5 years, Cash from Restructuring stood at -$10.0 million in 2010, then surged by 420.0% to $32.0 million in 2011, then slumped by 96.88% to $1.0 million in 2012, then sank by 800.0% to -$7.0 million in 2013, then soared by 1325.57% to $85.8 million in 2014.
• The last three Cash from Restructuring figures came in at $85.8 million (Q2 2014), -$102.0 million (Q1 2014), and -$7.0 million (Q2 2013), per Business Quant data.